John Heymach, MD, PhD
Advertisement
Articles by John Heymach, MD, PhD
John Heymach, MD, reviews the evolving treatment landscape of EGFR+ metastatic non-small cell lung cancer.
John Heymach, MD, PhD, chair of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, discusses the characteristics of three more KRAS subsets in lung cancer, which researchers discovered in a recent study.
Advertisement
Latest Updated Articles
Improved Outcomes for Patients With EGFR+ NSCLCMay 21st 2020
Molecular Testing for Newly Diagnosed NSCLCMay 21st 2020
Repeat Testing at Progression of EGFR+ NSCLCMay 21st 2020
Treatment Options for EGFR+ NSCLCMay 21st 2020
Changing Landscape of EGFR+ mNSCLCMay 21st 2020
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
3
MC001 Receives FDA Fast Track Designation in Pancreatic Cancer
4
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
5